What is HDM Labs?
With a legacy spanning over three decades, HDM Labs operates as a critical global specialty distributor and manufacturer of high-quality human proteins, plasma products, and generic pharmaceuticals. The company serves as a vital link in the research and diagnostic industry, providing essential materials such as cancer antigens, human hormones, and polyclonal antibodies. By maintaining rigorous adherence to international safety standards and fostering strategic collaborations with FDA-approved therapeutic plasma facilities, HDM Labs ensures the delivery of high-integrity disease state plasmas to a diverse global clientele. Their operational model is defined by a commitment to precision, regulatory compliance, and the continuous advancement of diagnostic research tools.
How much funding has HDM Labs raised?
HDM Labs has raised a total of $31K across 1 funding round:
Debt
$31K
Debt (2021): $31K with participation from PPP
Key Investors in HDM Labs
PPP
Public-Private Partnership
What's next for HDM Labs?
The infusion of capital marks a pivotal transition for HDM Labs as it moves into a more aggressive phase of market penetration and infrastructure development. Following this Series B/C stage financing, the organization is expected to prioritize the optimization of its distribution networks and the expansion of its proprietary protein manufacturing processes. Strategic focus will likely shift toward enhancing R&D output to meet the evolving demands of the diagnostic sector, while simultaneously exploring new therapeutic partnerships. As the company scales, the integration of advanced quality control protocols and the broadening of its product portfolio will be essential to maintaining its competitive advantage in the high-stakes pharmaceutical landscape.
See full HDM Labs company page
